Through purpose-driven science, empowering medicines, and transformative advocacy we seek to improve the lives of millions.
Our areas of focus
An estimated 19 million women in the U.S. have uterine fibroids.
An estimated 7.5 million premenopausal women in the U.S. have endometriosis.
Approximately 3 million men alive today in the U.S. have been diagnosed with prostate cancer.
Myovant is developing innovative medicines that hold promise to improve people’s lives.
5 Aug 2022
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
27 Jul 2022
Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022
13 Jul 2022
Myovant Sciences to Host First Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on July 27, 2022
30 Jun 2022
Myovant Statement: U.S. Supreme Court Ruling in Dobbs v. Jackson Women’s Health Organization
You are leaving www.myovant.com, a website provided by Myovant Sciences GmbH.
This link will take you to a different site.